Edgewise Therapeutics (EWTX) to Release Earnings on Thursday

Edgewise Therapeutics (NASDAQ:EWTX) is expected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Edgewise Therapeutics to post earnings of ($0.39) per share for the quarter.

Edgewise Therapeutics Trading Up 2.1 %

NASDAQ EWTX opened at $26.67 on Thursday. Edgewise Therapeutics has a 1-year low of $14.90 and a 1-year high of $38.12. The stock has a 50-day moving average of $27.62 and a 200-day moving average of $27.13. The firm has a market cap of $2.53 billion, a PE ratio of -17.78 and a beta of 0.20.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on EWTX. Truist Financial boosted their target price on Edgewise Therapeutics from $33.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, November 27th. Evercore ISI upped their price target on Edgewise Therapeutics from $45.00 to $50.00 and gave the company an “outperform” rating in a research report on Tuesday, December 17th. Wedbush upped their price target on Edgewise Therapeutics from $44.00 to $45.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Finally, Stifel Nicolaus started coverage on Edgewise Therapeutics in a research report on Wednesday, January 22nd. They set a “hold” rating and a $30.00 price target for the company. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $41.29.

Insiders Place Their Bets

In other Edgewise Therapeutics news, insider Alan J. Russell sold 1,200 shares of the company’s stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $30.13, for a total transaction of $36,156.00. Following the transaction, the insider now owns 14,863 shares in the company, valued at approximately $447,822.19. This represents a 7.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Marc Semigran sold 29,709 shares of the company’s stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $29.69, for a total value of $882,060.21. Following the transaction, the insider now owns 6,716 shares in the company, valued at $199,398.04. This trade represents a 81.56 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 164,545 shares of company stock worth $4,605,305. Company insiders own 24.11% of the company’s stock.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.